Nanotechnology approaches for personalized treatment of multidrug resistant cancers

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1880-1895

  Minko, Tamara ^a,b   Rodriguez Rodriguez, Lorna ^b,c   Pozharov, Vitaly ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Antisense oligonucleotides; Cancer stem cells; CD44; Drug delivery system; LHRH; Passive and active targeting; Peptides; Pump and nonpump resistance; SiRNA

Indexed keywords

ACTIVE TARGETING; ANTISENSE OLIGONUCLEOTIDES; CANCER STEM CELLS; CD44; DRUG DELIVERY SYSTEM; LHRH; SIRNA;

ANTIBODIES; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; DRUG DOSAGE; DRUG INTERACTIONS; PEPTIDES; STEM CELLS;

PATIENT TREATMENT;

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BRYOSTATIN 1; CAMPTOTHECIN; CHLOROQUINE; CYCLOSPORIN A; DOXORUBICIN; EMODIN; HONOKIOL; LIPOSOME; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NANOCARRIER; NIFEDIPINE; PRENYLAMINE; PROGESTERONE; PROPOFOL; PROTEIN BCL 2; QUINIDINE; QUININE; SMALL INTERFERING RNA; TAMOXIFEN; TIAPAMIL; TRABECTEDIN; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINDOLINE; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; ENDOCYTOSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; IC 50; LUNG CANCER; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TARGETED PROAPOPTOTIC DRUG DELIVERY SYSTEM;

A DOSE THAT KILLS 50% OF CELLS; ABC; ADENOSINE TRIPHOSPHATE (ATP)-BINDING CASSETTE; ANTIBODY; ANTISENSE OLIGONUCLEOTIDES; ASO; CAMPTOTHECIN; CANCER STEM CELLS; CD44; CPT; DBD; DDS; DOX; DOXORUBICIN; DRUG DELIVERY SYSTEM; DRUG-BINDING DOMAIN; ENHANCED PERMEABILITY AND RETENTION EFFECT; EPR; IC(50) DOSE; LHRH; LUTEINIZING HORMONE-RELEASE HORMONE; NANOSTRUCTURED LIPID CARRIERS; NBD; NLC; NUCLEOTIDE-BINDING DOMAIN; PAMAM; PASSIVE AND ACTIVE TARGETING; PEPTIDES; POLY(AMIDO AMINE); PUMP AND NONPUMP RESISTANCE; SINGLE-NUCLEOTIDE POLYMORPHISM; SIRNA; SMALL INTERFERING RNA; SNP; TARGETED PROAPOPTOTIC DRUG DELIVERY SYSTEM; TMD; TPADDS; TRANSMEMBRANE DOMAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASMS;

EID: 84888199558     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.017     Document Type: Review

References (155)

1. Rebucci M., Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem. Pharmacol. 2013, 85:1219-1226.
2. Wu C.P., Hsieh C.H., Wu Y.S. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol. Pharm. 2011, 8:1996-2011.
3. Moulder S. Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond. Engl.) 2010, 6:821-830.
4. Ullah M.F. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac. J. Cancer Prev. 2008, 9:1-6.
5. Pauwels E.K., Erba P., Mariani G., Gomes C.M. Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect. 2007, 20:371-377.
6. Teoh D., Secord A.A. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int. J. Gynecol. Cancer 2012, 22:348-359.
7. Slovin S. Chemotherapy and immunotherapy combination in advanced prostate cancer. Clin. Adv. Hematol. Oncol. 2012, 10:90-100.
8. Inoue K., Narukawa M., Takeuchi M. Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials. Lung 2012, 190:355-364.
9. Hodge J.W., Ardiani A., Farsaci B., Kwilas A.R., Gameiro S.R. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin. Oncol. 2012, 39:323-339.
10. Bhattacharyya S., Khanduja K.L. New hope in the horizon: cancer stem cells. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42:237-242.
11. Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14:3-9.
12. Fabian A., Barok M., Vereb G., Szollosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology?. Cytometry A 2009, 75:67-74.
13. Mimeault M., Mehta P.P., Hauke R., Batra S.K. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr. Rev. 2008, 29:234-252.
14. Shah V., Taratula O., Garbuzenko O.B., Taratula O.R., Rodriguez-Rodriguez L., Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin. Cancer Res. 2013, Sep. 13 [Epub ahead of print].
15. Minko T., Pakunlu R.I., Wang Y., Khandare J.J., Saad M. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem. 2006, 6:537-552.
16. Pakunlu R.I., Cook T.J., Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res. 2003, 20:351-359.
17. Pakunlu R.I., Wang Y., Saad M., Khandare J.J., Starovoytov V., Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release 2006, 114:153-162.
18. Pakunlu R.I., Wang Y., Tsao W., Pozharov V., Cook T.J., Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res. 2004, 64:6214-6224.
19. Tiwari A.K., Sodani K., Dai C.L., Ashby C.R., Chen Z.S. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 2011, 12:570-594.
20. Chen Z.S., Tiwari A.K. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011, 278:3226-3245.
21. Noguchi K., Katayama K., Mitsuhashi J., Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev. 2009, 61:26-33.
22. Natarajan K., Xie Y., Baer M.R., Ross D.D. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharmacol. 2012, 83:1084-1103.
23. van Veen H.W., Konings W.N. The ABC family of multidrug transporters in microorganisms. Biochim. Biophys. Acta 1998, 1365:31-36.
24. Loo T.W., Clarke D.M. Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein. Biochem. Cell Biol. 1999, 77:11-23.
25. Chaudhry P., Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr. Relat. Cancer 2009, 16:363-380.
26. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000, 407:810-816.
27. Dharap S.S., Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm. Res. 2003, 20:889-896.
28. Dharap S.S., Wang Y., Chandna P., Khandare J.J., Qiu B., Gunaseelan S., et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12962-12967.
29. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G., Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10737-10742.
30. Khandare J.J., Chandna P., Wang Y., Pozharov V.P., Minko T. Novel polymeric prodrug with multivalent components for cancer therapy. J. Pharmacol. Exp. Ther. 2006, 317:929-937.
31. Taratula O., Garbuzenko O.B., Kirkpatrick P., Pandya I., Savla R., Pozharov V.P., et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release 2009, 140:284-293.
32. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171:349-357.
33. Zhang M., Garbuzenko O.B., Reuhl K.R., Rodriguez-Rodriguez L., Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine (Lond.) 2012, 7:185-197.
34. Minko T., Dharap S.S., Pakunlu R.I., Wang Y. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 2004, 5:389-406.
35. Minko T., Kopeckova P., Kopecek J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 1999, 16:986-996.
36. Minko T., Kopeckova P., Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 2000, 86:108-117.
37. Sinha B.K. Free radicals in anticancer drug pharmacology. Chem. Biol. Interact. 1989, 69:293-317.
38. Sinha B.K., Mimnaugh E.G. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic. Biol. Med. 1990, 8:567-581.
39. Getoff N. Vitamin free radicals and their anticancer action. Review. In Vivo 2009, 23:599-611.
40. Jaggi A.S., Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012, 291:1-9.
41. Lokeshwar B.L. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol. Res. 2011, 63:146-150.
42. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011, 71:1385-1396.
43. Tertil M., Jozkowicz A., Dulak J. Oxidative stress in tumor angiogenesis-therapeutic targets. Curr. Pharm. Des. 2010, 16:3877-3894.
44. Niki E., Yoshida Y., Saito Y., Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem. Biophys. Res. Commun. 2005, 338:668-676.
45. Yin H., Xu L., Porter N.A. Free radical lipid peroxidation: mechanisms and analysis. Chem. Rev. 2011, 111:5944-5972.
46. Cheeseman K.H. Mechanisms and effects of lipid peroxidation. Mol. Aspects Med. 1993, 14:191-197.
47. Amara A.A. The philosophy behind exo/endo/existing antioxidants and our built-in oxidant and antioxidant system. Pharmazie 2010, 65:711-719.
48. Irshad M., Chaudhuri P.S. Oxidant-antioxidant system: role and significance in human body. Indian J. Exp. Biol. 2002, 40:1233-1239.
49. Bounous G., Molson J.H. The antioxidant system. Anticancer Res 2003, 23:1411-1415.
50. Fernandez V., Videla L.A. Biochemical aspects of cellular antioxidant systems. Biol. Res. 1996, 29:177-182.
51. Vera-Ramirez L., Sanchez-Rovira P., Ramirez-Tortosa M.C., Ramirez-Tortosa C.L., Granados-Principal S., Lorente J.A., et al. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit. Rev. Oncol. Hematol. 2011, 80:347-368.
52. Shan L. 99mTc-Labeled doxorubicin 2004, Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD).
53. Zunino F., Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 1990, 5:307-317.
54. Berger W.E., Noonan M.J. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler. J. Asthma 2010, 47:447-459.
55. Molimard M., Till D., Stenglein S., Singh D., Krummen M. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Curr. Med. Res. Opin. 2007, 23:2405-2413.
56. Palmieri T.L. Use of beta-agonists in inhalation injury. J. Burn Care Res. 2009, 30:156-159.
57. de Lange D.W., Meulenbelt J. Do corticosteroids have a role in preventing or reducing acute toxic lung injury caused by inhalation of chemical agents?. Clin. Toxicol. (Phila.) 2011, 49:61-71.
58. Frampton J.E. Mometasone/formoterol inhalation aerosol: in asthma uncontrolled on medium- or high-dose inhaled corticosteroids. Drugs 2012, 72:1229-1241.
59. Konstan M.W., VanDevanter D.R., Rasouliyan L., Pasta D.J., Yegin A., Morgan W.J., et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr. Pulmonol. 2010, 45:1167-1172.
60. Heijerman H., Westerman E., Conway S., Touw D., Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009, 8:295-315.
61. Parkins M.D., Elborn J.S. Tobramycin Inhalation Powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev. Respir. Med. 2011, 5:609-622.
62. Zeitler K., Salvas B., Stevens V., Brown J. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am. J. Health Syst. Pharm. 2012, 69:107-115.
63. O'Riordan T., Faris M. Inhaled antimicrobial therapy. Respir. Care Clin. N. Am. 1999, 5:617-631.
64. Rodvold K.A., Yoo L., George J.M. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin. Pharmacokinet. 2011, 50:689-704.
65. Kinsella J.P., Ivy D.D., Abman S.H. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: acute, late, and chronic pulmonary hypertension. Semin. Perinatol. 2005, 29:123-128.
66. Kondili E., Georgopoulos D. Aerosol medications. Respir. Care Clin. N. Am. 2002, 8:309-334. (viii-ix).
67. Haas D.A. Oral and inhalation conscious sedation. Dent. Clin. N. Am. 1999, 43:341-359.
68. Paterson S.A., Tahmassebi J.F. Paediatric dentistry in the new millennium: 3. Use of inhalation sedation in paediatric dentistry. Dent. Update 2003, 30:350-356. (8).
69. Ivanova V., Garbuzenko O.B., Reuhl K.R., Reimer D.C., Pozharov V.P., Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur. J. Pharm. Biopharm. 2013, 84:335-344.
70. Minko T., Stefanov A., Pozharov V. Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol. J. Appl. Physiol. 2002, 93:1550-1560. discussion 49.
71. Savla R., Minko T. Nanotechnology approaches for inhalation treatment of fibrosis. J. Drug Target. 2013, Aug. 27 [Epub ahead of print].
72. Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. 2009, 26:382-394.
73. Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 2011, 19:900-914.
74. Schwerdt J.I., Goya G.F., Calatayud M.P., Herenu C.B., Reggiani P.C., Goya R.G. Magnetic field-assisted gene delivery: achievements and therapeutic potential. Curr. Gene Ther. 2012, 12:116-126.
75. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
76. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
77. Thanou M., Duncan R. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr. Opin. Investig. Drugs 2003, 4:701-709.
78. Minko T. HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance. Adv. Drug Deliv. Rev. 2010, 62:192-202.
79. Minko T., Kopeckova P., Pozharov V., Jensen K.D., Kopecek J. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm. Res. 2000, 17:505-514.
80. Khan M.Z., Stedul H.P., Kurjakovic N. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. Drug Dev. Ind. Pharm. 2000, 26:549-554.
81. Nykanen P., Lempaa S., Aaltonen M.L., Jurjenson H., Veski P., Marvola M. Citric acid as excipient in multiple-unit enteric-coated tablets for targeting drugs on the colon. Int. J. Pharm. 2001, 229:155-162.
82. Sinha V.R., Kumria R. Binders for colon specific drug delivery: an in vitro evaluation. Int. J. Pharm. 2002, 249:23-31.
83. Chourasia M.K., Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003, 6:33-66.
84. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev. 2004, 56:491-509.
85. Shareef M.A., Khar R.K., Ahuja A., Ahmad F.J., Raghava S. Colonic drug delivery: an updated review. AAPS PharmSci 2003, 5:E17.
86. Mansour A.M., Drevs J., Esser N., Hamada F.M., Badary O.A., Unger C., et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003, 63:4062-4066.
87. Bae M., Cho S., Song J., Lee G.Y., Kim K., Yang J., et al. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis. Drugs Exp. Clin. Res. 2003, 29:15-23.
88. Guo X., Szoka F.C. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc. Chem. Res. 2003, 36:335-341.
89. Harashima H., Shinohara Y., Kiwada H. Intracellular control of gene trafficking using liposomes as drug carriers. Eur. J. Pharm. Sci. 2001, 13:85-89.
90. Luzio J.P., Parkinson M.D., Gray S.R., Bright N.A. The delivery of endocytosed cargo to lysosomes. Biochem. Soc. Trans. 2009, 37:1019-1021.
91. Sorkin A., Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat. Rev. Mol. Cell Biol. 2002, 3:600-614.
92. Minko T. Receptor mediated delivery systems for cancer therapeutic. Advances in Delivery Science and Technology 2012, 329-355. CRS Press, Springer. R. Siegel, S. Juergen, M. Rathbone (Eds.).
93. Omelyanenko V., Kopeckova P., Gentry C., Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release 1998, 53:25-37.
94. Chu T.W., Yang J., Kopecek J. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis. Biomaterials 2012, 33:7174-7181.
95. David A., Kopeckova P., Minko T., Rubinstein A., Kopecek J. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur. J. Cancer 2004, 40:148-157.
96. Fowers K.D., Kopecek J. Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates. Macromol. Biosci. 2012, 12:502-514.
97. Kunath K., Kopeckova P., Minko T., Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur. J. Pharm. Biopharm. 2000, 49:11-15.
98. Lu Z.R., Kopeckova P., Kopecek J. Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nat. Biotechnol. 1999, 17:1101-1104.
99. Minko T., Patil M.L., Zhang M., Khandare J.J., Saad M., Chandna P., et al. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol. Biol. 2010, 624:281-294.
100. Savla R., Taratula O., Garbuzenko O., Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Release 2011, 153:16-22.
101. Chandna P., Khandare J.J., Ber E., Rodriguez-Rodriguez L., Minko T. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm. Res. 2010, 27:2296-2306.
102. Chandna P., Saad M., Wang Y., Ber E., Khandare J., Vetcher A.A., et al. Targeted proapoptotic anticancer drug delivery system. Mol. Pharm. 2007, 4:668-678.
103. Dharap S.S., Chandna P., Wang Y., Khandare J.J., Qiu B., Stein S., et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy. J. Pharmacol. Exp. Ther. 2006, 316:992-998.
104. Dharap S.S., Qiu B., Williams G.C., Sinko P., Stein S., Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J. Control. Release 2003, 91:61-73.
105. Saad M., Garbuzenko O.B., Ber E., Chandna P., Khandare J.J., Pozharov V.P., et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J. Control. Release 2008, 130:107-114.
106. Taratula O., Garbuzenko O., Savla R., Wang Y.A., He H., Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug Deliv. 2011, 8:59-69.
107. Behnam-Motlagh P., Tyler A., Grankvist K., Johansson A. Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy. Toxins (Basel) 2010, 2:2467-2477.
108. Saha S., Adhikary A., Bhattacharyya P., Das T., Sa G. Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res 2012, 32:2567-2584.
109. Ganguly A., Banerjee K., Chakraborty P., Das S., Sarkar A., Hazra A., et al. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative. Biomed. Pharmacother. 2011, 65:387-394.
110. Galano G., Caputo M., Tecce M.F., Capasso A. Efficacy and tolerability of vinorelbine in the cancer therapy. Curr. Drug Saf. 2011, 6:185-193.
111. Ye W., Chang H.L., Wang L.S., Huang Y.W., Shu S., Dowd M.K., et al. Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil. Anticancer Res 2007, 27:107-116.
112. Tang J., Wang Y., Wang D., Xu Z., Racette K., Liu F. Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules 2013, 14:424-430.
113. Shrivastava P., Hanibuchi M., Yano S., Parajuli P., Tsuruo T., Sone S. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil. Cancer Chemother. Pharmacol. 1998, 42:483-490.
114. Abraham I., El Sayed K., Chen Z.S., Guo H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar. Drugs 2012, 10:2312-2321.
115. Baumert C., Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem. 2009, 9:415-436.
116. Abbasi M., Lavasanifar A., Uludag H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med. Res. Rev. 2013, 33:33-53.
117. Stewart D.J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit. Rev. Oncol. Hematol. 2010, 75:173-234.
118. Morjani H., Madoulet C. Immunosuppressors as multidrug resistance reversal agents. Methods Mol. Biol. 2010, 596:433-446.
119. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 2006, 13:1859-1876.
120. Wu C.P., Ohnuma S., Ambudkar S.V. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 2011, 12:609-620.
121. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond.) 2008, 3:761-776.
122. Rodriguez-Rodriguez L., Sancho-Torres I., Leakey P., Gibbon D.G., Comerci J.T., Ludlow J.W., et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol. Oncol. 1998, 71:223-229.
123. Rodriguez-Rodriguez L., Sancho-Torres I., Mesonero C., Gibbon D.G., Shih W.J., Zotalis G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med. Oncol. 2003, 20:255-263.
124. Yao C.J., Lai G.M., Yeh C.T., Lai M.T., Shih P.H., Chao W.J., et al. Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/beta-catenin signaling and apoptosis induction. Evid.-Based Complement. Altern. Med. 2013, 2013:146136.
125. Lin W., Zheng L., Zhuang Q., Zhao J., Cao Z., Zeng J., et al. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway. BMC Complement. Altern. Med. 2013, 13:144.
126. Kim S.M., Park J.H., Kim K.D., Nam D., Shim B.S., Kim S.H., et al. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades. Phytother. Res. 2013, May 20 [Epub ahead of print].
127. Kim C., Kim M.C., Kim S.M., Nam D., Choi S.H., Kim S.H., et al. Chrysanthemum indicum L. extract induces apoptosis through suppression of constitutive STAT3 activation in human prostate cancer DU145 cells. Phytother. Res. 2013, 27:30-38.
128. Zhou J., Hu S.E., Tan S.H., Cao R., Chen Y., Xia D., et al. Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion in human cancer cells. Autophagy 2012, 8:338-349.
129. Lin S.Z., Wei W.T., Chen H., Chen K.J., Tong H.F., Wang Z.H., et al. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS One 2012, 7:e42146.
130. Hahm E.R., Singh S.V. Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. Cancer Lett. 2013, 334:101-108.
131. Wang P., Chen J., Mu L.H., Du Q.H., Niu X.H., Zhang M.Y. Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. Eur. Rev. Med. Pharmacol. Sci. 2013, 17:1722-1729.
132. Saturno G., Valenti M., De Haven Brandon A., Thomas G.V., Eccles S., Clarke P.A., et al. Combining trail with pI3 kinase or hsp90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget 2013, 4:1185-1198.
133. Hwang K.E., Park D.S., Kim Y.S., Kim B.R., Park S.N., Lee M.K., et al. Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis. Int. J. Oncol. 2013, 43:72-78.
134. Nagaoka I., Tamura H., Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J. Immunol. 2006, 176:3044-3052.
135. Minko T., Dharap S.S., Fabbricatore A.T. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense. Cancer Detect. Prev. 2003, 27:193-202.
136. Chen A.M., Taratula O., Wei D., Yen H.I., Thomas T., Thomas T.J., et al. Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes. ACS Nano 2010, 4:3679-3688.
137. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
138. Sturrock A., Seedahmed E., Mir-Kasimov M., Boltax J., McManus M.L., Paine R. GM-CSF provides autocrine protection for murine alveolar epithelial cells from oxidant-induced mitochondrial injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:L343-L351.
139. Zhu J.H., Hong D.F., Song Y.M., Sun L.F., Wang Z.F., Wang J.W. Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells. Asian Pac. J. Cancer Prev. 2013, 14:1017-1021.
140. Pan B., Zheng S., Liu C., Xu Y. Suppression of IGHG1 gene expression by siRNA leads to growth inhibition and apoptosis induction in human prostate cancer cell. Mol. Biol. Rep. 2013, 40:27-33.
141. Duan J., Lang Y., Song C., Xiong J., Wang Y., Yan Y. siRNA targeting of PRDX3 enhances cisplatininduced apoptosis in ovarian cancer cells through the suppression of the NFkappaB signaling pathway. Mol. Med. Rep. 2013, 7:1688-1694.
142. Akagi H., Higuchi H., Sumimoto H., Igarashi T., Kabashima A., Mizuguchi H., et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 2013, 16:100-110.
143. Xu Y., Li C., Tian Q., Li Y., Yang Z., Liang Z., et al. Suppression of lung cancer metastasis-related protein 1 promotes apoptosis in lung cancer cells. Int. J. Mol. Med. 2012, 30:1481-1486.
144. Yang G., Wu D., Zhu J., Jiang O., Shi Q., Tian J., et al. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol. Rep. 2013, 30:877-889.
145. Wang Y., Minko T. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug. Biochem. Pharmacol. 2004, 68:2031-2042.
146. Wang Y., Pakunlu R.I., Tsao W., Pozharov V., Minko T. Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis. Mol. Pharm. 2004, 1:156-165.
147. Wang Y., Saad M., Pakunlu R.I., Khandare J.J., Garbuzenko O.B., Vetcher A.A., et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clin. Cancer Res. 2008, 14:3607-3616.
148. Zhao A., Zeng Q., Xie X., Zhou J., Yue W., Li Y., et al. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. J. Genet. Genomics 2012, 39:29-35.
149. Shah V., Taratula O., Garbuzenko O.B., Patil M.L., Savla R., Zhang M., et al. Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr. Drug Discov. Technol. 2013, 10:8-15.
150. Patil M.L., Zhang M., Betigeri S., Taratula O., He H., Minko T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug. Chem. 2008, 19:1396-1403.
151. Patil M.L., Zhang M., Taratula O., Garbuzenko O.B., He H., Minko T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009, 10:258-266.
152. Patil M.L., Zhang M., Minko T. Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano 2011, 5:1877-1887.
153. Fornari F.A., Randolph J.K., Yalowich J.C., Ritke M.K., Gewirtz D.A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 1994, 45:649-656.
154. Momparler R.L., Karon M., Siegel S.E., Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976, 36:2891-2895.
155. Hinds M., Deisseroth K., Mayes J., Altschuler E., Jansen R., Ledley F.D., et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 1991, 51:4729-4731.